Calgary, Alberta – April 13, 2026 – Marvel Biosciences Corp. (TSXV: MRVL) (“Marvel” or the “Company”) Further tothe Company’s press release of April 8, 2026, announcing its intention to complete a non-brokered private placementoffering of unsecured convertible...
Calgary, Alberta – April 8, 2026 – Marvel Biosciences Corp. (TSXV: MRVL) (“Marvel” or the “Company”) announced today its intention to complete a non-brokered private placement offering of unsecured convertible debentures (“Debentures”) in the principal amount of...
Calgary, Alberta – March 30, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel therapeutics for autism spectrum...
Calgary, Alberta – March 25, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel, therapeutics for autism spectrum...
Calgary, Alberta – March 18, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel, therapeutics for autism spectrum...
